June 2019 - Volume 3 - Issue - Contributor Index

Author:
La Cava, P.

GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY: PF585

Romano, A.; Parrinello, N. L.; Simeon, V.; More

HemaSphere. 3:244, June 2019.

Author:
La Marca, G.
Author:
La Nasa, G.
Author:
La Sala, E.
Author:
La Starza, R.

TARGETING ONCOGENIC NOTCH1 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH A NEW SELECTIVE SERCA INHIBITOR CAD204520: PF158

Marchesini, M.; Gherli, A.; Winter, A.-M. Lund; More

HemaSphere. 3:31, June 2019.

Author:
Laadem, A.
Author:
Laas, C.

LEVELS OF BCL2 EXPRESSION AT POST-INDUCTION AND AT COMPLETE REMISSION IMPACT THE OUTCOME IN AML AND MAY IDENTIFY THOSE PATIENTS THAT WOULD BENEFIT OF BCL2 INHIBITORS: PB1689

Bilbao, C.; Medina, Rodríguez C.; Sosa, Sánchez S.; More

HemaSphere. 3:778, June 2019.

RUXOLITINIB IN POLYCYTHEMIA VERA PATIENTS: RESPONSE DIFFERENCES BETWEEN IN HYDROXYUREA INTOLERANT AND RESISTANT PATIENTS: PB2233

Pérez, González E.; FernándezFuertes, F.; Sánchez, Raya J. M.; More

HemaSphere. 3:1001, June 2019.

Author:
Labopin, M.

POST-TRANSPLANT CYCLOPHOSPHAMIDE VS ATG FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN T-REPLETE HAPLOIDENTICAL TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A REPORT OF THE ALWP/EBMT: S114

Nagler, A.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9, June 2019.

IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD: S115

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9-10, June 2019.

Author:
Labotka, R.

DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL - ANALYSIS FROM THE TOURMALINE-MM3 STUDY: PS1382

Goldschmidt, H.; Dimopoulos, M. A.; Rajkumar, S. V.; More

HemaSphere. 3:632-633, June 2019.

Author:
Labrador, G.

REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE: PF757

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3:332-333, June 2019.

Author:
Labrador, J.

ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL: PF216

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J. M.; More

HemaSphere. 3:59, June 2019.

PROGNOSTIC VALUE OF NEXT GENERATION FLOW MONITORING CIRCULATING TUMOR PLASMA CELLS IN PERIPHERAL BLOOD ON MYELOMA PATIENTS AFTER TREATMENT: PF555

Flores, Sanoja L.; Montero, Flores J.; Contreras-Sanfeliciano, T.; More

HemaSphere. 3:230, June 2019.

RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT: PS1398

Dávila, J.; González-Calle, V.; Puig, N.; More

HemaSphere. 3:641-642, June 2019.

Author:
Labrijn, A.
Author:
Labuhn, M.

JANUS KINASE AND CYTOKINE RECEPTOR MUTATIONS IN TRANSIENT ABNORMAL MYELOPOIESIS AND MYELOID LEUKEMIA IN CHILDREN WITH TRISOMY 21: PS998

Labuhn, M.; Perkins, K.; Papaemmanuil, E.; More

HemaSphere. 3:449, June 2019.

IMPACT OF MESURABLE RESIDUAL DISEASE POSITIVITY ON OUTCOMES FOLLOWING UNMBILICAL CORD BLOOD TRANSPLANTATION: A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT AND EUROCORD: S115

Baron, F.; Labopin, M.; Ruggeri, A.; More

HemaSphere. 3:9-10, June 2019.

Author:
LaCasce, A.

THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS: S867

Advani, R.; Bartlett, N.; Smith, S.; More

HemaSphere. 3:388, June 2019.

Author:
LaCasce, A. S.

IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-ARM, MULTICENTER, PHASE 2 TRIAL: PF374

Davids, M. S.; Brander, D. M.; Kim, H. T.; More

HemaSphere. 3:138-139, June 2019.

Author:
Lacayo, N. J.

COMBINATION BCL-2 INHIBITOR THERAPY WITH VENETOCLAX AND NAVITOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA: PS940

Pullarkat, V. A.; Stock, W.; Lacayo, N. J.; More

HemaSphere. 3:423-424, June 2019.

Author:
Lacerda, J.
Author:
Lachmann, H.

BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: PB2127

Mahmood, A. S.; Sachchithanantham, S.; Harrison, S.; More

HemaSphere. 3:958, June 2019.

Author:
Lachot, S.
Author:
Lacombe, F.
Author:
Lacut, K.
Author:
Lacy, M.
Author:
Lad, D. P.

A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL TRIAL OF DAILY VERSUS ALTERNATE DAY ORAL IRON IN TREATMENT OF IRON DEFICIENCY ANEMIA: PF498

Lad, D. P.; Kaundal, R.; Bhatia, P.; More

HemaSphere. 3:201-202, June 2019.

Author:
Ladab, S.
Author:
Ladaique, A.
Author:
Laddaga, F. E.
Author:
Ladeb, S.
Author:
Ladetto, M.

COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL: PS1248

Ferrero, S.; Zaccaria, G. M.; Barbero, D.; More

HemaSphere. 3:569-570, June 2019.

QPCR, MFC AND DDPCR: COMPARISON ON MRD SAMPLES FROM THREE PROSPECTIVE TRIALS OF THE EUROPEAN MCL NETWORK: PS1312

Drandi, D.; Alcantara, M.; Barbero, D.; More

HemaSphere. 3:599, June 2019.

Author:
Ladikou, E.
Author:
Ladislau, L.
Author:
Ladogana, S.
Author:
Ladygina, E.

EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION: PS1104

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3:500, June 2019.

Author:
Laetsch, T. W.

TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH-RISK CYTOGENETIC ABNORMALITIES: S1618

Grupp, S.; Maude, S.; Baruchel, A.; More

HemaSphere. 3:746-747, June 2019.

Author:
Lafaurie, M.
Author:
Laffan, M.
Author:
Lafrance, W.
Author:
Lagache, S.
Author:
Lagarde, S.

RAS/MAPK ACTIVATION COOPERATES WITH GAIN OF CHROMOSOME 21 IN B CELL LEUKEMIA AND IS AN ATTRACTIVE TARGET TO IMPROVE THE OUTCOME OF DS CHILDREN WITH B-ALL: PF151

Laurent, A. P.; Siret, A.; Ignacimouttou, C.; More

HemaSphere. 3:28, June 2019.

Author:
Lagarkova, M.

PROSPECTIVE COMPARISON OF SANGER SEQUENCING VS NEXT GENERATION SEQUENCING FOR ROUTINE BCR-ABL1 KINASE DOMAIN MUTATION SCREENING IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS: PF172

Soverini, S.; Martelli, M.; Bavaro, L.; More

HemaSphere. 3:37-38, June 2019.

Author:
Lagreca, I.

EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY: PS1274

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3:583, June 2019.

Author:
Lagrou, K.

CLINICAL IMPLICATIONS OF AZOLE-RESISTANT VERSUS AZOLE-SUSCEPTIBLE INVASIVE ASPERGILLOSIS IN HEMATOLOGICAL MALIGNANCY (CLARITY) - A MULTICENTER STUDY: PS1283

Cornely, O. A.; Seidel, D.; Arenz, D.; More

HemaSphere. 3:587, June 2019.

Author:
Laguna, P.
Author:
Lahav, M.
Author:
Lahoz, C.
Author:
Lahr, C.
Author:
Lahuerta, J. J.

BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PF594

Rosiñol, L.; Hebraud, B.; Oriol, A.; More

HemaSphere. 3:249-250, June 2019.

HEAVY&LIGHT CHAIN MONITORING IN HIGH RISK SMOLDERING MULTIPLE MYELOMA PATIENTS INCLUDED IN THE GEM-CESAR TRIAL: COMPARISON WITH CONVENTIONAL AND MINIMAL RESIDUAL DISEASE IMWG RESPONSE ASSESSMENT: PF609

Puig, N.; Contreras, T.; Paiva, B.; More

HemaSphere. 3:258, June 2019.

CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL: PS1351

Ubieto, Jiménez A.; Martinez-Lopez, J.; Paiva, B.; More

HemaSphere. 3:617, June 2019.

DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS: PS1352

Puig, N.; Paíno, T.; Pérez, J. J.; More

HemaSphere. 3:617-618, June 2019.

Author:
Lahuerta, J.-J.

SINGLE-CELL CHARACTERIZATION OF THE MULTIPLE MYELOMA (MM) IMMUNE MICROENVIRONMENT IDENTIFIES CD27- T CELLS AS POTENTIAL SOURCE OF TUMOR-REACTIVE LYMPHOCYTES: S121

Botta, C.; Perez, C.; Puig, N.; More

HemaSphere. 3:12-13, June 2019.

CURATIVE STRATEGY (GEM-CESAR) FOR HIGH-RISK SMOLDERING MYELOMA: CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (KRD) AS INDUCTION FOLLOWED BY HDT-ASCT, CONSOLIDATION WITH KRD AND MAINTENANCE WITH RD: S871

Mateos, M.-V.; Martínez-López, J.; Rodríguez-Otero, P.; More

HemaSphere. 3:390, June 2019.

DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM): PS1348

Pérez, C.; Botta, C.; Zabaleta, A.; More

HemaSphere. 3:615-616, June 2019.

Author:
Lai, Y.
Author:
Lai, Y.-H.
Author:
Lai, Y.-Y.
Author:
Laille, E.
Author:
Laina, A.

FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA: PS1394

Kastritis, E.; Laina, A.; Gavriatopoulou, M.; More

HemaSphere. 3:639-640, June 2019.

Author:
Lainé, D.

SUCCESSOR: A MULTICENTER RETROSPECTIVE NONINTERVENTIONAL FOLLOW-UP STUDY IN PATIENTS WITH SICKLE CELL PAIN CRISES WHO PREVIOUSLY PARTICIPATED IN THE SUSTAIN TRIAL IN THE UNITED STATES: S853

Liles, D.; Shah, N.; Scullin, B.; More

HemaSphere. 3:380-381, June 2019.

Author:
Lainey, E.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Lak, N.
Author:
Lakhal, A.
Author:
Lakhwani, S.

CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY: PS1186

Garcia-Gutierrez, V.; Hernandez-Boluda, J. C.; Moiraghi, B.; More

HemaSphere. 3:540-541, June 2019.

Author:
Lakshmi, T. J.
Author:
Lal, A.

RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSAEMIA AND A β0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE: S140

Kulozik, A. E.; Locatelli, F.; Yannaki, E.; More

HemaSphere. 3:21-22, June 2019.

Author:
Lal, I.
Author:
Lal, L.
Author:
Lala, J.
Author:
Lalayanni, C.

RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOME: PF191

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3:47-48, June 2019.

Author:
Lalayianni, C.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IMPROVES SURVIVAL IN AML PATIENTS WITH HIGH FLT3-ITD ALLELIC RATIO: PB1750

Papalexandri, A.; Kika, F.; Varelas, C.; More

HemaSphere. 3:804-805, June 2019.

Show: